Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study aimed to estimate the value of urine prostate specific antigen (uPSA) as a marker for benign prostatic hyperplasia (BPH) but reported no new clinical findings.

This study concluded that incorporating the percentage of free PSA and urinary markers improves the accuracy of determining the need for prostate biopsy.

Long-term diabetes is linked to lower prostate cancer risk.

This study found no clear evidence that finasteride negatively affects erectile function, though it does cause a reduction in ejaculatory volume and has potential implications for prostate cancer risk.

Finasteride treats enlarged prostate and baldness, but may cause limited urinary improvement and sex-related side effects.

This study found that 5-alpha-reductase inhibitor monotherapy for symptomatic benign prostatic hyperplasia showed some clinical benefit over placebo but was linked to a higher incidence of sexual side effects.

This case report suggests that spironolactone may induce prostate cancer proliferation in patients on abiraterone acetate, advising against its use for managing treatment-associated side effects in these individuals.

This review discusses the expression of PSA in hormonally-regulated tissues and female malignancies, emphasizing its potential as a diagnostic biomarker and role in antidoping initiatives.

This study reports that 5-alpha-reductase inhibitors do not prevent prostate cancer and merely reduce the likelihood of undergoing diagnostic biopsies, potentially misleading patients and physicians.

Finasteride treats hair loss but may affect prostate cancer detection.

In this study on testosterone-induced benign prostatic hyperplasia in rats, hydroxychloroquine significantly reduced prostate-related markers and enhanced therapeutic effects when combined with finasteride, suggesting potential as a new treatment approach.

In this study, FMN was found to inhibit androgen receptor function and androgen-regulated gene expression in prostate cancer cells, suggesting potential as an antiandrogen therapy.

Systematic end-of-trial biopsies are the most reliable way to assess outcomes.

This editorial comment reports no new clinical findings, instead discussing a study on the effectiveness of combination therapy with doxazosin and finasteride in patients with benign prostatic hyperplasia.

This case report from the authors highlights a rare diagnosis of high-grade prostate cancer in a 35-year-old man, showing strong functional recovery and no detectable PSA one year after robotic-assisted radical prostatectomy despite the usual onset being significantly later in life.

The document does not confirm if radical prostatectomy is the best treatment for locally advanced prostate cancer.

This study found that some cancer cells exhibit neuronal-like characteristics, which may serve as a mechanism of resistance.

This study calculated the molecular properties of finasteride using PM3 methods, providing insights into its characteristics despite the lack of published data on these properties.

Dihydrotestosterone gel improved well-being and sexual function in older men without negatively affecting prostate health.

In this study, 1 mg/day finasteride lowered serum PSA concentration in men aged 40–60, suggesting that PSA adjustment recommendations for prostate cancer screening using 5 mg/day finasteride should also apply to this lower dose for hair loss treatment.

This study found that Ganoderma lucidum extracts reduced prostate enlargement and improved symptoms in testosterone-treated rats, suggesting potential benefits for managing benign prostatic hyperplasia.

This review discusses the stratification and management of male patients with lower urinary tract symptoms and benign prostatic hyperplasia in primary care and reports no new clinical results.

This study found that Monascus cursory extraction reduced baldness, prostate hyperplasia, and tumor incidence in animal models of androgen-related diseases, suggesting it may be a promising new therapeutic candidate.

Combination therapy for BPH is cost-effective, especially for men with larger prostates.

Most white Spanish women have a widow's peak, and their hairline measurements could help in hair restoration surgery.

This review concludes that while many epidemiological studies suggest high alcohol intake is associated with an increased risk of prostate cancer, the evidence may be affected by confounding factors such as diet and lifestyle.

This study found that Caesalpinia bonduc seed extracts significantly reduced prostate weight and improved prostate tissue morphology in Wistar rats with testosterone-induced benign prostatic hyperplasia.

This study found that Tripterygium wilfordii multiglycoside significantly inhibited testosterone-induced benign prostatic hyperplasia in rats without causing toxicity, suggesting its potential as a therapy for BPH.

Finasteride is beneficial for BPH but requires careful monitoring due to cancer risks.

This study found that dutasteride improved maximum urinary flow rate more effectively than finasteride when used in combination therapy with tamsulosin for treating benign prostatic hyperplasia over six months.